369 related articles for article (PubMed ID: 23479568)
41. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
[TBL] [Abstract][Full Text] [Related]
42. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
[TBL] [Abstract][Full Text] [Related]
43. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
44. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
[TBL] [Abstract][Full Text] [Related]
45. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.
Palladini G; Sachchithanantham S; Milani P; Gillmore J; Foli A; Lachmann H; Basset M; Hawkins P; Merlini G; Wechalekar AD
Blood; 2015 Jul; 126(5):612-5. PubMed ID: 25987656
[TBL] [Abstract][Full Text] [Related]
46. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
47. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
48. Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change.
D'Souza A; Brazauskas R; Dispenzieri A; Panepinto J; Flynn KE
Blood Cancer J; 2021 Feb; 11(2):29. PubMed ID: 33563897
[TBL] [Abstract][Full Text] [Related]
49. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
Palladini G; Foli A; Milani P; Russo P; Albertini R; Lavatelli F; Obici L; Perlini S; Moratti R; Merlini G
Am J Hematol; 2012 May; 87(5):465-71. PubMed ID: 22389105
[TBL] [Abstract][Full Text] [Related]
50. Impaired right ventricular function as a predictor of early mortality in patients with light‑ chain cardiac amyloidosis assessed in a cardiology department.
Szczygieł JA; Wieczorek PZ; Drozd-Sokołowska J; Michałek P; Mazurkiewicz Ł; Legatowicz-Koprowska M; Walczak E; Jędrzejczak WW; Dwilewicz-Trojaczek J; Grzybowski J
Pol Arch Intern Med; 2017 Dec; 127(12):854-864. PubMed ID: 29112180
[TBL] [Abstract][Full Text] [Related]
51. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
Gustine JN; Staron A; Mendelson L; Joshi T; Gopal DM; Siddiqi OK; Ruberg FL; Sanchorawala V
Blood Adv; 2023 Oct; 7(20):6080-6091. PubMed ID: 37581513
[TBL] [Abstract][Full Text] [Related]
52. Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis.
Lilleness B; Doros G; Ruberg FL; Sanchorawala V
Br J Haematol; 2020 Feb; 188(3):424-427. PubMed ID: 31515797
[TBL] [Abstract][Full Text] [Related]
53. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.
Palladini G; Barassi A; Perlini S; Milani P; Foli A; Russo P; Albertini R; Obici L; Lavatelli F; Sarais G; Casarini S; Moratti R; Melzi d'Eril GV; Merlini G
Amyloid; 2011 Dec; 18(4):216-21. PubMed ID: 22070520
[TBL] [Abstract][Full Text] [Related]
54. Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.
Sachchithanantham S; Offer M; Venner C; Mahmood SA; Foard D; Rannigan L; Lane T; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
Haematologica; 2015 Nov; 100(11):1469-76. PubMed ID: 26294730
[TBL] [Abstract][Full Text] [Related]
55. The Real-World Data on Patients With Cardiac Stage IIIb AL Amyloidosis.
Hong Y; Guo J; Chen W; Zhao L; Liu Z; Huang X
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38806310
[TBL] [Abstract][Full Text] [Related]
56. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.
Wechalekar AD; Lachmann HJ; Goodman HJ; Bradwell A; Hawkins PN; Gillmore JD
Blood; 2008 Nov; 112(10):4009-16. PubMed ID: 18708629
[TBL] [Abstract][Full Text] [Related]
57. Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial.
Masson S; Wu JH; Simon C; Barlera S; Marchioli R; Mariani J; Macchia A; Lombardi F; Vago T; Aleksova A; Dreas L; Favaloro RR; Hershson AR; Puskas JD; Dozza L; Silletta MG; Tognoni G; Mozaffarian D; Latini R;
Eur J Clin Invest; 2015 Feb; 45(2):170-8. PubMed ID: 25510286
[TBL] [Abstract][Full Text] [Related]
58. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
59. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
60. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
